Project overview
Recent studies have shown the promising role of Janus Kinase (JAK) inhibitors in treating alopecia areata, an autoimmune disorder characterized by non-scarring hair loss and cessation of hair growth. 
This 2-page mock magazine spread seeks to elucidate how JAK inhibitors affect the JAK/STAT pathway, inhibiting T-cell proliferation and subsequent inflammation associated with the collapse of hair follicles' immune privilege seen in individuals with this condition. The "anatomy" of half of a JAK protein is clarified, along with how a JAK inhibitor, such as Ruxolitinib, binds in the active site of the JAK tyrosine kinase domain, inhibiting JAK's ability to phosphorylate other proteins in the JAK/STAT pathway.

Main References
Davis, R. R., & Schonbrunn, E. (2021). 6VGL - JAK2 JH1 in complex with ruxolitinib. RCSB PDB Protein Data Bank. https://www.rcsb.org/structure/6vgl

Divito, S. J., & Kupper, T. S. (2014). Inhibiting Janus kinases to treat alopecia areata. Nature Medicine, 20(9), 989-990.

Leroy, E., & Constantinescu, S. N. (2017). Rethinking JAK2 Inhibition: Towards Novel Strategies of More Specific and Versatile Janus Kinase Inhibition. Leukemia, 31(5), 1023–1038. 

Process work to come.